Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane | Synapse
January 21, 2015Open Access
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Key Points
Key points are not available for this paper at this time.
Abstract
In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.